Abstract:Recent evidence has suggested that breast cancer contains a rare population of cells called cancer stem cells (CSCs), which have an extensive self-renewal ability and contribute to metastasis and therapeutic resistance. This study evaluated the in vitro and in vivo effects of RAD001 (Everolimus) alone or in combination with docetaxel on stem cells from primary breast cancer cells and two breast cancer cell lines (MCF-7 and MDA-MB-231). In In vitro studies, we sorted ESA+CD44+CD24−/low cells as stem cells using flow cytometry from primary breast cancer cells, MCF-7 and MDA-MB-231 cell lines. MTT assays were used to quantify the inhibitory effect of the drugs on total cells and stem cells. Apoptosis and the cell cycle distributions of stem cells were examined by flow cytometry. The tumourigenicity of stem cells after treatment was investigated by soft agar colony formation assays. In In vivo studies, the BALB/c mice were injected with MDA-MB-231 stem cells and the different treatments were administered. After necropsy, the expression of Ki67, CD31, AKT1, and phospho-AKT (Thr308) was analysed by immunohistochemistry. In In vitro studies, all three populations of stem cells were resistant to the standard treatment doses of docetaxel compared with total cells treated with the same drug. Treatment with RAD001 resulted in growth inhibition of all stem cells in a dose-dependent manner. An additive growth inhibitory effect of the combination treatment on the three stem cells was observed in in vitro compared with treatment with RAD001 alone (P<0.001). In addition, an increase in G2/M cell cycle arrest and an increased population of cells in early apoptosis were seen in the combination treatment group compared with either single-agent group (P<0.01). In vivo, the volumes of the xenograft tumours significantly decreased in RAD001 alone group compared to control group (P=0.008), and RAD001 plus docetaxel therapy was much more effective at reducing tumour volume in mice compared with either single-agent alone (P<0.05). Compared with RAD001 alone, the combination of RAD001 and docetaxel reduced the expression of Ki67, CD31, AKT1 and phospho-AKT (Thr308) (P<0.05). We conclude that the combination treatment of RAD001 and docetaxel can inhibit the growth of stem cells in vitro and in vivo by inhibiting cell proliferation, inducing apoptosis, cell cycle arrest and reducing the expression of Ki67, CD31, AKT1 and phospho-AKT (Thr308). These data indicate that combination treatment with RAD001 and docetaxel may represent an effective therapy for breast cancer. However, further studies are required to evaluate the drug interaction between RAD001 and docetaxel in the clinical setting.

Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer.

Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway.

Doxycycline Induces Apoptosis and Inhibits Proliferation and Invasion of Human Cervical Carcinoma Stem Cells

Doxycycline Inhibits the Adhesion and Migration of Melanoma Cells by Inhibiting the Expression and Phosphorylation of Focal Adhesion Kinase (FAK).

Doxycycline Reverses Epithelial-to-mesenchymal Transition and Suppresses the Proliferation and Metastasis of Lung Cancer Cells

Cyclin D1 Affects Epithelial–mesenchymal Transition in Epithelial Ovarian Cancer Stem Cell-Like Cells

1 Chemical Therapeutics Q 1 2 Doxycycline as an Inhibitor of the Epithelial-to-Mesenchymal 3 Transition and Vasculogenic Mimicry in Hepatocellular Q 2 4 Carcinoma 5 6

Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)

Bardoxolone Methyl Induces Apoptosis and Autophagy and Inhibits Epithelial-to-mesenchymal Transition and Stemness in Esophageal Squamous Cancer Cells.

Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy

Stat3/Oct-4/c-Myc Signal Circuit for Regulating Stemness-Mediated Doxorubicin Resistance of Triple-Negative Breast Cancer Cells and Inhibitory Effects of WP1066.

Effects of the Combination of RAD001 and Docetaxel on Breast Cancer Stem Cells

Resveratrol Inhibits Breast Cancer Stem-Like Cells and Induces Autophagy Via Suppressing Wnt/β-catenin Signaling Pathway.

Inhibition of Mir-155, a Therapeutic Target for Breast Cancer, Prevented in Cancer Stem Cell Formation

Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer

Doxorubicin Promotes Migration and Invasion of Breast Cancer Cells through the Upregulation of the RhoA/MLC Pathway

An Epigenetic Mechanism Underlying Doxorubicin Induced EMT in the Human BGC-823 Gastric Cancer Cell.

Biodegradable polymeric micelle-encapsulated doxorubicin suppresses tumor metastasis by killing circulating tumor cells.

Compound Nanoemulsion Combined with Differentiation/Cytotoxicity Drugs for Modulating Breast Cancer Stemness.

Reduced Tumorigenicity and Drug Resistance Through the Downregulation of Octamer-Binding Protein 4 and Nanog Transcriptional Factor Expression in Human Breast Stem Cells

Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells